Navigation Links
Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Date:3/29/2009

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia. In Study HBBI, neither LY2140023 monohydrate, nor the comparator molecule olanzapine, known to be more effective than placebo, separated from placebo. In this particular study, Lilly observed a greater-than-expected placebo response, which was approximately double that historically seen in schizophrenia clinical trials.

Because inconclusive clinical trial results are common in the field of neuroscience and given the previous positive proof-of-concept study for this compound, Study HBBD, which was published in the September 2007 issue of the journal Nature Medicine, Lilly is continuing with the development of LY2140023 monohydrate. Lilly plans an additional Phase II study, Study HBBM, which if positive, would validate the HBBD proof-of-concept trial results.

Six hundred sixty nine patients enrolled in Study HBBI and 393 completed this four-week, in-patient trial. A higher-than-expected placebo response was observed (14.6 points improvement) as measured by the Positive and Negative Syndrome Scale (PANSS) total score. The primary analyses did not demonstrate that any of the four LY2140023 monohydrate doses (5, 20, 40 and 80 mg taken twice daily) separated from placebo. Similarly, olanzapine at 15mg once daily also did not separate from placebo. LY2140023 monohydrate was generally well- tolerated, although convulsions were observed in three patients. Furthermore, LY2140023 monohydrate had a low association with adverse events commonly associated with currently available antipsychotics and showed no appreciable weight gain.


'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Issues a Complete Response Letter for Lillys Olanzapine LAI for Treatment of Schizophrenia in Adults
2. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
3. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
4. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
5. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
8. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
9. Lilly and TransPharma Medical Announce Licensing and Development Agreement
10. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
11. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) ... Conference on Tuesday, June 9, 2015. Jeffrey Simmons ... will participate in a fireside chat at 2:20 p.m., ... webcast will be available on the "Webcasts & Presentations" ... A replay of the fireside chat will be available ...
(Date:5/29/2015)... SAN DIEGO and BOSTON ... a leader in instrument development, custom automation, and contract ... developer of the Nanopatch™ needle-free drug delivery technology, have ... for development of the Nanopatch Jet Coating Instrument ... drug delivery research and product development.  The award was ...
(Date:5/29/2015)... SAN DIEGO , May 29, 2015 /PRNewswire/ ... single cell sequencing data, from metastatic castrate resistant ... of the American Society for Clinical Oncology. This ... no cell left behind™ platform to ... study revealed that late stage patients have heterogeneous ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:5/29/2015)... Designed with the versatile athlete in mind, ... all new, exclusive line of supplementation called The 24/7 ... and greatest, high impact, result driven ingredients that have ... 24/7 Series can be used by anyone from bodybuilders ... fitness enthusiasts. There are no stimulant based ingredients that ...
(Date:5/29/2015)... The annual aesthetic meeting, put on by the American Society ... May 14-19th. This global event sets a gold standard ... dedicating itself exclusively to cosmetic medicine. Dr. Paul Vitenas ... to attend this year’s meeting. , Among the classes and ... the honor of sitting at the presenter’s table during a ...
(Date:5/29/2015)... 2015 The report “Axillary ... comprehensive information on the therapeutic development for ... by identifying new targets and MOAs to ... on H1 2015 pipeline review of Axillary ... 13 figures, spread across 47 pages is ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... 2015 DISC, a method of behavioral ... behavior, is used by companies to improve hiring practices, ... once considered an out-of-the-box practice, has now become an ... from the Society for Human Resource Management found that ... DISC to be an essential part of the hiring ...
Breaking Medicine News(10 mins):Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:PeopleKeys to Air a Follow-up to Their Popular DISC Trainer’s Toolbox Webinar, Featuring All-New Content and Strategies 2
... ... of award-winning natural skin and hair care products for children, is reminding ... rays and potential toxins found in many sunscreens. TruKid has always ... dioxane, BPA and paraben free, offering excellent UVA/UVB protection SPF. We ...
... ... of Medical Genetics to meet virtual repository technology needs of the network, , ... Reston, VA (PRWEB) June ... the American College of Medical Genetics (ACMG) has selected the company to contribute web-based ...
... ... Ferro achieved explosive sales growth of 427 percent between 2007 - 2009 to qualify for ... described as a “win/win/win for all involved.” , ... Marlton, NJ (PRWEB) June 15, 2010 -- Amid all the ...
... ... must be eliminated to stop the terrible human suffering and environmental toll exacted through ... difference. , ... June 15, 2010 -- Adrian Desbarats, owner of an organic clothing company ...
... OAK BROOK, Ill. A new study suggests that computed ... of having pulmonary embolism (PE), based on the results of ... exposure and costs associated with CT angiography. The results of ... issue of the journal Radiology . ...
... could prevent 100,000 deaths worldwide each year, study suggests ... drug commonly used to prevent excess bleeding in surgeries ... after trauma, a new study suggests. , The drug, ... world and easily administered, experts said. It works by ...
Cached Medicine News:Health News:TruKid, the Award-Winning Line of Natural Products for Children, Wants to Help Keep your Kids Safe in the Sandbox this Summer 2Health News:TruKid, the Award-Winning Line of Natural Products for Children, Wants to Help Keep your Kids Safe in the Sandbox this Summer 3Health News:Technology Innovation Advances Newborn Screen Translational Research Network 2Health News:Technology Innovation Advances Newborn Screen Translational Research Network 3Health News:Free For All Honored for Explosive Growth, 2007 – 2009 2Health News:Free For All Honored for Explosive Growth, 2007 – 2009 3Health News:Organic Clothing – Is Your Clothing Delivering Death in Small Doses? 2Health News:Organic Clothing – Is Your Clothing Delivering Death in Small Doses? 3Health News:CT angiography may be unnecessary in patients with suspected pulmonary embolism 2Health News:Drug That Stops Bleeding Could Save Lives 2Health News:Drug That Stops Bleeding Could Save Lives 3
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D...
... Sur-Catch NT stone retrieval basket raises proven tipless, ... unique paired wire design and multi-sizing basket enable ... of each patient and procedure. Its highly ... with the DURTM-8 Elite Ureteroscope and its ergonomic ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Medicine Products: